Suzhou Dawnrays Pharmaceutical Co., Ltd.

Primary objective: To compare the differences in the extent and rate of absorption of rosuvastatin ezetimibe tablets (I) (specification: 10 mg / 10 mg) produced by Fujian Dongrui Pharmaceutical Co., Ltd. and rosuvastatin ezetimibe tablets (I) (specification: 10 mg / 10 mg, brand name: Zhilida®/Zenon®) licensed by Sanofi-Aventis Ireland Limited T/A SANOFI in healthy adults under fasting and postprandial administration conditions, and to evaluate their bioequivalence. Secondary objective: To evaluate the safety of rosuvastatin ezetimibe tablets (I) (10 mg / 10 mg) under fasting and postprandial administration conditions.

Main study objectives To evaluate the pharmacokinetics of the test preparation crisaborole ointment (specification: 2% (30g: 0.6g), produced by Suzhou Dongrui Pharmaceutical Co., Ltd.) and the reference preparation crisaborole ointment (trade name: Sutanming®, specification: 2%, 30g, licensed by Anacor Pharmaceuticals, Inc.) in healthy Chinese adult subjects after single topical application under fasting conditions, and to evaluate the bioequivalence of the two preparations in the fasting state. Secondary study objectives To evaluate the safety of the test preparation crisaborole ointment (specification: 2% (30g: 0.6g), produced by Suzhou Dongrui Pharmaceutical Co., Ltd.) and the reference preparation crisaborole ointment (trade name: Sutanming®, specification: 2%, 30g, licensed by Anacor Pharmaceuticals, Inc.) in healthy Chinese subjects.

The pharmacokinetics of the test preparation benidipine hydrochloride tablets (specification: 8 mg, produced and provided by Fujian Dongrui Pharmaceutical Co., Ltd.) and the reference preparation benidipine hydrochloride tablets (Colirol®, specification: 8 mg; certified by Kyowa Kirin Co., Ltd., provided by Fujian Dongrui Pharmaceutical Co., Ltd.) were studied in healthy adult subjects after a single oral administration under fasting/fed state, and the bioequivalence of the two preparations under fasting/fed state was evaluated.